Flashlight-Trigger Solution from Assay Designs/Stressgen Bioreagents
...lity shift assay (EMSA) is a powerful tool for eva...o as gel shift or gel retardation, the assay is ba...ophoresis, free DNA will migrate differently than ...luminescent EMSA Kit is a nonradioactive system fo...
...real-time PCR detection system holds 48 x 0.2 ml t... independently excites fluorescence (470-500 nm) f...etects emitted light (523-543 nm and 540-700 nm). ... MJ Mini thermal cycler. System dimensions are 18 ...
... provide automated, higher throughput screening of...tubes. This flexible sample format makes the Guava...rch, target validation, assay development, and eve...uava PCA-96 uses a green laser detection system an...
Biology Products:(Date:11/30/2009)...dge, Mass November 30, 2009 An international tea...otonics, and ETH Zrich have demonstrated compact, ... the invisible part of the light spectrum (infrare...t beam of a well-defined wavelength. The innovativ...ons related to remote chemical sensing pollution m...
(Date:11/30/2009)..., NEW YORK, Nov. 30 Th...ch (MJFF) today announced $1.5 million in total aw...ntially disease-modifying therapies for Parkinson,...l Approaches to Drug Discovery for Parkinson,s Dis...Corporation, plc (NYSE: ELN ), a neuroscience-ba...
(Date:11/30/2009)..., AMSTERDAM, November 30 Biop...y that the first patients have been enrolled in it...TIR(TM). The study is,designed to show reduction i...r following an allogeneic stem cell transplantatio...od cancer patients eligible for an allogeneic,stem...
(Date:11/30/2009)..., ROCKVILLE, Md., Nov. 30 /PRNewswire-FirstCall/ ...it has completed enrollment in the Phase II clinic.../2009 recommended strains) VLP vaccine candidate i...dults). This randomized, double-blind, active-con...y and immunogenicity of two different doses (15 mc...
Breaking Biology Technology:Scientists demonstrate multibeam, multi-functional lasers 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4